APR 17, 2018 12:51 PM PDT

New Experimental Model for ALS and MS Immunotherapies

WRITTEN BY: Kara Marker

A new mouse model allows researchers to study the impact of immune cell function in the brain on diseases like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). With the hope of developing new immunotherapies for these diseases, researchers from the Karolinska Institutet use the model in a new study.

MRI of someone with amyotrophic lateral sclerosis. Credit: Dr. Frank Gaillard

Immune cells called monocytes travel through to blood into the brain and damage neurons and the myelin sheath, a protective layer of tissue that promotes the transmission of nerve impulses. In ALS, neurons controlling voluntary muscle movement are affected. These are the neurons responsible for chewing, walking, and talking. Over time, these neurons deteriorate completely. Most people with ALS die from respiratory failure three to five years after they first develop symptoms.

With MS, an autoimmune disease and the most common neurological disease affecting young adults, the immune system mistakenly attacks the myelin sheath, affecting neurons in the brain and spinal cord. People with MS experience numbness, weakness, and pain in the arms and legs, vision loss, tremors, fatigue, dizziness, bowel and bladder dysfunction. Over 400,000 people in the United States and 2.5 million people across the globe are affected by MS.

Macrophages are phagocytic cells, which means they serve the immune system by engulfing and digesting bacteria and other unfriendly objects they come across. Macrophages in the brain, called microglia, specialize in function as directed by the cytokine TGF-β. Can TGF-β prevent monocytes from becoming harmful, instead alter them to function positively like the microglia?

"We already knew that TGF-β is produced in the brain and is important for giving microglia their specialised functions," explained first author Harald Lund. "So we figured that monocytes should also respond to TGF-β when they enter the brain. We were curious to see what would happen if the monocytes lost the ability to respond to TGF-β."

Using the new model, researchers removed the mice’s microglia. This resulted in monocytes rushing into the brain and spinal cord, mimicking the activity of microglia and causing no pathological symptoms. But when researchers inhibited TGF-β activity, the monocytes started to destroy the myelin in the spinal cord, and a lethal neurodegenerative disease developed. The symptoms of that disease looked just like ALS.

In the future, researchers could use a similar model to test more aspects of diseases like ALS and MS, as well as test new potential immunotherapies.

"There are many deadly neurodegenerative diseases in humans, but a lack of experimental models for developing new immunotherapies," explained Bob Harris, PhD. "This new disease model will be a valuable addition to our research programme and we hope that the next study will result in a new, effective therapy."

The present study was published in the journal Nature Immunology.

Sources: Karolinska Institutet, Discovery MS, Mayo Clinic, National Institute of Neurological Disorders and Stroke

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 03, 2020
Clinical & Molecular DX
MAR 03, 2020
Singapore charges ahead with antibody-based test for COVID-19
Researchers, biotech and pharmaceutical companies are scrambling to put an end to the coronavirus disease (COVID-19) out ...
MAR 05, 2020
Drug Discovery & Development
MAR 05, 2020
Human Stem Cells Cure Type 1 Diabetes in Mice
In the US alone, around 187,000 children and adolescents have Type 1 diabetes, alongside 1.4 million people aged 20 and ...
MAR 19, 2020
Drug Discovery & Development
MAR 19, 2020
Could a 1949 Malaria Drug Treat COVID-19?
In the race to halt the current coronavirus pandemic, scientists, health experts and even Elon Musk are considering chlo ...
MAR 28, 2020
Drug Discovery & Development
MAR 28, 2020
Could the Blood of Coronavirus Survivors Save Lives?
As the search for a treatment for coronavirus continues, a perhaps obscure-sounding candidate has begun to make headline ...
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
MAY 19, 2020
Immunology
MAY 19, 2020
The Mystery of the Life-Saving Vaccine Solved
In the early 1900s, French bacteriologists Albert Calmette and Camille Guerin spent the better half of a decade developi ...
Loading Comments...